Details of the Drug Reposition

General Information of This Drug (ID: DM91LGU)

Drug Name
Abexinostat   DM91LGU
Synonyms
PCI-24781; 783355-60-2; ABEXINOSTAT; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Follicular lymphoma DISVEUR6 2A80 Phase 3 [1]
Renal cell carcinoma DISQZ2X8 2C90 Phase 3 [2]
------------------------------------------------------------------------------------
6 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [1]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 2 [1]
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 2 [1]
Peripheral T-cell lymphoma DISCDT4E 2A90.C Phase 2 [1]
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [1]
Gynecologic cancer DIST2NIJ 2F33-2F76 Phase 2 [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT03592472) A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV). U.S. National Institutes of Health.